Rachel J. Nagashima

Rachel J. Nagashima

Partner

Rachel Nagashima is a partner in the Palo Alto office of Wilson Sonsini Goodrich & Rosati, where she practices corporate and securities law. Rachel represents both public and private companies on general corporate and transactional matters, including public company disclosure matters, venture financings, and corporate governance.

Experience

Education

J.D., Osgoode Hall Law School, York University, Toronto, 2013
B.A., Honours Business Administration, Richard Ivey School of Business, The University of Western Ontario, 2010

Admissions

State Bar of California

Credentials

Education

J.D., Osgoode Hall Law School, York University, Toronto, 2013
B.A., Honours Business Administration, Richard Ivey School of Business, The University of Western Ontario, 2010

Admissions

State Bar of California

Recent Insights

Client Highlights

On January 29, 2026, ESS Tech, a leading manufacturer of long-duration energy storage systems (LDES) for commercial and utility-scale applications, announced that it has entered into definitive agreements in a registered direct offering with institutional investors for the purchase and sale of approximately $15 million of shares of common stock and pre-funded warrants at a price of $1.75 per share of common stock, which price was a premium to the closing price on January 28, 2026. Wilson Sonsini Goodrich & Rosati advised ESS Tech on the transaction.

Learn More

Client Highlights

On June 16, 2025, Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics, announced the close of its underwritten public offering of 9,920,987 shares of its common stock, which includes the full exercise of the underwriters' option to purchase 1,526,250 additional shares of its common stock, at a price to the public of $19.66 per share and pre-funded warrants to purchase 1,780,263 shares of its common stock at a price to the public of $19.659 per pre-funded warrant. All of the shares and pre-funded warrants were sold by Enliven. The gross proceeds from the offering were approximately $230 million before deducting underwriting discounts and commissions and other offering expenses. Wilson Sonsini Goodrich & Rosati advised Enliven on the offering.

Learn More